# Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV

> **NCT01866930** · PHASE3 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 453 (actual)

## Conditions studied

- Chronic Hepatitis C Infection

## Interventions

- **BIOLOGICAL:** Pegylated Interferon Lambda-1a
- **DRUG:** Daclatasvir (DCV)
- **DRUG:** Ribasphere (RBV)

## Key facts

- **NCT ID:** NCT01866930
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07-11
- **Primary completion:** 2015-08-27
- **Final completion:** 2015-08-27
- **Target enrollment:** 453 (ACTUAL)
- **Why stopped:** Sponsor decision not based on any new unexpected safety findings or efficacy observations.
- **Last updated:** 2023-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01866930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01866930, "Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01866930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*